logo

Myriad Genetics Inc. (MYGN)



Trade MYGN now with
  Date
  Headline
11/4/2019 4:11:00 PM Myriad Genetics Q1 Loss/share $0.28 Vs. Loss $0.01 Year Ago
10/21/2019 7:08:16 AM Myriad Genetics Names Mark Pollack Chief Medical Officer Of Myriad Neuroscience, Effective Jan. 15
9/16/2019 7:26:58 AM Myriad Genetics Enters Research Collaboration With University Of Leeds
8/22/2019 7:14:53 AM Myriad Genetics Applauds USPSTF Recommendation On BRCA-Related Cancer Prevention
8/13/2019 4:08:36 PM Myriad Genetics Q4 Loss/share $0.06 Vs. Profit 0.20 Year Ago
8/7/2019 7:26:51 AM Myriad To Seek FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Men With MCRPC
6/19/2019 7:13:35 AM Myriad Genetics Gets Second Insurance Reimbursement Decision For BRACAnalysis
5/7/2019 4:14:18 PM Myriad Genetics Q3 Adjusted EPS $0.46 Vs $0.34 Last Year
4/9/2019 7:07:45 AM Myriad Genetics Submits First Module Of Premarket Approval Application To FDA For MyChoice HRD CDx Test
2/5/2019 4:06:56 PM Myriad Genetics Q2 EPS $0.03 Vs. $0.43 Year Ago
12/31/2018 7:07:15 AM Myriad Genetics Says Former CEO Peter Durkee Meldrum, 71, Passed Away On December 20, 2018
12/26/2018 7:14:48 AM Myriad Publishes Vectra Study In Journal Rheumatology
12/19/2018 7:09:13 AM Myriad Genetics : EndoPredict Test Receives Positive NICE Recommendation For Patients With Early Breast Cancer
  
 
>